Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Camurus ABCAMRF +9.38%85 Intrinsic Value: Projected FCF is $13.88 as of Aug. 18, 2026, which is 41% above its 10-year median of 9.85. GuruFocus rates CAMRF with a GF Score™ of 85/100 and a GF Value™ of $75.36 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 258 Biotechnology companies, Camurus AB ranks worse than 74.03% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-08-18), Camurus AB's Intrinsic Value: Projected FCF is $13.88. The stock price of Camurus AB is $64.00. Therefore, Camurus AB's Price-to-Intrinsic-Value-Projected-FCF of today is 4.6.
The historical rank and industry rank for Camurus AB's Intrinsic Value: Projected FCF or its related term are showing as below:
CAMRF'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 3.91 Med: 9.85 Max: 302.25
Current: 4.61
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Camurus AB was 302.25. The lowest was 3.91. And the median was 9.85.
CAMRF's Price-to-Projected-FCF is ranked worse than 74.03% of 258
companies
in the Biotechnology industry
Industry Median: 2.205
vs CAMRF: 4.61
Camurus AB (OTCPK:CAMRF) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Camurus AB's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
64.00
/
13.449883763738
=
4.76
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camurus AB Intrinsic Value: Projected FCF Related Terms
Camurus AB Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Camurus AB's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAMRF vs VRTX, REGN, RVMD: Intrinsic Value: Projected FCF Comparison
For the Biotechnology subindustry, Camurus AB's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB Price-to-Projected-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Camurus AB's Price-to-Projected-FCF falls into.
Camurus AB Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $13.88 mean?
Camurus AB (CAMRF) has a Intrinsic Value: Projected FCF of $13.88 as of Aug. 18, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Camurus AB and its competitors. This is 41% above median its historical median of 9.85. Over the past decade, Camurus AB's Intrinsic Value: Projected FCF has ranged from 3.91 to 302.25. According to the industry distribution chart, Camurus AB ranks #191 out of 258 companies in the Biotechnology industry, placing it in the top 74%.
Is Camurus AB's Intrinsic Value: Projected FCF too high?
Camurus AB's current Intrinsic Value: Projected FCF of $13.88 is 41% above median its 10-year median of 9.85. Over the past 10 years, this metric has ranged from a low of 3.91 to a high of 302.25. The Biotechnology industry median Intrinsic Value: Projected FCF is 2.21. Camurus AB's value of $13.88 is 529.5% above this industry median. Based on the distribution chart, Camurus AB ranks #191 out of 258 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Camurus AB has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Intrinsic Value: Projected FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #191 out of 258 companies for Intrinsic Value: Projected FCF. This places Camurus AB in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 2.21. Camurus AB's value of $13.88 is 529.5% above this benchmark. Historically, Camurus AB's own Intrinsic Value: Projected FCF has ranged from 3.91 to 302.25 over the past decade. While the company's 10-year median is 9.85 vs. the industry median of 2.21, Camurus AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Biotechnology company?
The median Intrinsic Value: Projected FCF among Biotechnology companies is 2.21, based on 258 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current Intrinsic Value: Projected FCF of $13.88 is 529.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Camurus AB and its competitors. For the Biotechnology industry, the median Intrinsic Value: Projected FCF is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current Intrinsic Value: Projected FCF is $13.88, which is 41% above median its own 10-year median of 9.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $75.36, compared to a current price of $64.00 — trading 15.1% below its estimated fair value. The current Intrinsic Value: Projected FCF is $13.88, which is 41% above median its 10-year median of 9.85 and 529.5% above the Biotechnology industry median of 2.21. Camurus AB's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Intrinsic Value: Projected FCF is $13.88 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $64.00 is trading 15.1% below its estimated GF Value™ of $75.36.
GuruFocus considers Camurus AB to be Modestly Undervalued.
Key valuation signals for CAMRF:
Intrinsic Value: Projected FCF: $13.88 (41% above median its 10-year median of 9.85)
GF Value™: $75.36 vs. price of $64.00 (15.1% below fair value)
Industry Position: 529.5% above the Biotechnology median (#191 of 258)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
85GF Score
Get the complete analysis for CAMRF
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
